
Astrazeneca Plc raised its outlook for 2022 revenue as sales of its Covid-19 therapies offset a decline in its coronavirus vaccine.
The UK drugmaker now expects revenues to rise by more than 20% this year, according to a statement Friday that showed its second-quarter earnings beat analysts’ estimates.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app